BioSpace News Archive

AstraZeneca and Merck to Seek Regulatory Approval for Lynparza in Pancreatic Cancer

Olivier Nataf, head of AstraZeneca’s U.S. oncology business unit, is excited about the potential the company’s PARP inhibitor Lynparza is showing as a potential treatment of pancreatic cancer.

June 3, 2019
·
3 min read
·
Alex Keown
Business

Biocartis and Kite Sign Agreement for Development of Assays supporting Kite’s Therapies

Biocartis Group NV, an innovative molecular diagnostics company, announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company.

June 3, 2019
·
7 min read
Business

Rentschler Fill Solutions appoints Dr. Friedrich Sernetz as Chief Executive Officer

Rentschler Fill Solutions GmbH announced the appointment of Dr. Friedrich Sernetz as Chief Executive Officer (CEO). Dr. Sernetz’ appointment became effective as of June 1, 2019.

June 3, 2019
·
5 min read
Boryung Pharmaceutical Korea increases production efficiency thanks to Aflex Hose

Aflex Hose from Watson-Marlow Fluid Technology Group is being used to manufacture Gelfos, the leading antacid medication in Korea, China and Taiwan

June 3, 2019
·
2 min read
Policy

Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Reviva Pharmaceuticals, Inc. announced that it has successfully completed a pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration for its drug candidate brilaroxazine, which is being developed for the treatment of idiopathic pulmonary fibrosis.

June 3, 2019
·
4 min read
Drug Development

Xolair (Omalizumab) Significantly Reduced Nasal Polyps and Congestion Symptoms in Adults with Chronic Rhinosinusitis with Nasal Polyps in Two Phase III Studies

Genentech, a member of the Roche Group, announced positive topline data from two Phase III multicenter studies evaluating Xolair® for the treatment of adults with chronic rhinosinusitis with nasal polyps who have not adequately responded to intranasal corticosteroids.

June 3, 2019
·
9 min read
Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination

Targovax ASA announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a humanized mouse melanoma model has been accepted for publication in the Journal of Medical Virology.

June 3, 2019
·
2 min read
Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination - June 3, 2019

Targovax ASA announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a humanized mouse melanoma model has been accepted for publication in the Journal of Medical Virology.

June 3, 2019
·
2 min read
Business

Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer

Carisma Therapeutics Inc. announced Robert Petit, Ph.D., as its Chief Scientific Officer.

June 3, 2019
·
2 min read
Business

Lyndra Therapeutics Welcomes Dr. Patricia Hurter as Chief Executive Officer

Addition to management team strengthens Lyndra’s development capabilities

June 3, 2019
·
3 min read